Monalizumab (Anti-Human CD159a)

Ask supplier a question | View on supplier's website

Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

Supplier	Selleck Chemicals
Product #	A2053
Sku #	A2053-1mg*25
Pricing	1mg*25, $5990.00

Feedback